Maxim Group

Steakholder Foods Ltd is a deep-tech food company focused on revolutionizing protein manufacturing through innovative 3D printing technologies. The company is dedicated to creating sustainable and high-quality alternative meat and seafood products that closely mimic the taste and texture of traditional proteins. By developing proprietary three-dimensional bioprinting techniques, Steakholder aims to improve meat production, streamline the supply chain, and provide consumers with a diverse range of offerings. Its mission includes reducing the environmental impact of food production by minimizing carbon footprints, water usage, and land requirements, while also eliminating the need for animal slaughter. Through its advanced manufacturing solutions, Steakholder Foods is positioning itself as a leader in the plant-based and cultivated meat industry, committed to supporting partners in the rapidly evolving market.

Nacuity Pharmaceuticals, Inc. is a biotechnology company based in Fort Worth, Texas, founded in 2016. The company focuses on developing innovative treatments for retinitis pigmentosa and other ophthalmological disorders. Nacuity aims to address ocular oxidative stress and various ocular diseases through its drug candidates. It has garnered substantial support from the Foundation Fighting Blindness, which has invested significantly in research aimed at preventing, treating, and curing blinding retinal diseases. This collaboration includes funding for Nacuity’s Phase 1 and Phase 2 trials related to its NPI-001 development program, reflecting a commitment to advancing therapies for patients affected by these conditions.

Alveo Technologies, Inc., established in 2014 and based in Alameda, California, specializes in developing infectious disease diagnostic devices. The company's core product, be.well, is a comprehensive system that includes nasal swabs, disposable cartridges, a handheld analyzer, and a cloud-based diagnostics platform. This integrated platform combines nucleic acid detection with molecular biochemistry to identify illnesses such as Flu A/B, COVID-19, and Respiratory Syncytial Virus (RSV). By leveraging cutting-edge advances in sensing, microfluidics, and bioassays, Alveo aims to empower consumers, healthcare professionals, and treatment providers with faster, more informed decisions, ultimately contributing to better health outcomes and personalized medicine.

Abeona Therapeutics is a clinical-stage biopharmaceutical company focused on developing gene and cell therapies for life-threatening rare genetic diseases. Its lead programs include EB-101, an autologous, gene-corrected cell therapy for recessive dystrophic epidermolysis bullosa; ABO-102, an adeno-associated virus-based gene therapy for Sanfilippo syndrome type A; and ABO-101, an AAV-based gene therapy for Sanfilippo syndrome type B. The company also develops therapies for Batten disease, cystic fibrosis, and genetic eye disorders. Additionally, Abeona Therapeutics is advancing the AIM Vector Platform, which includes over 100 next-generation AAV capsids for delivering gene therapies to various organs. The company operates a manufacturing facility producing therapies and vectors for preclinical and clinical studies.

Edge Therapeutics is a clinical-stage biotechnology company based in Berkeley Heights, New Jersey, focused on developing innovative therapies for acute, life-threatening neurological conditions. Established in 2009, the company aims to transform treatment paradigms in hospital settings through its proprietary platform, Precisa, which facilitates the creation of polymer-based therapeutics designed for targeted delivery to injury sites. The lead product candidate, EG-1962, is currently undergoing evaluation in the Phase 3 NEWTON 2 study, aimed at improving outcomes for patients suffering from aneurysmal subarachnoid hemorrhage (aSAH). Additionally, Edge is assessing EG-1964 as a potential prophylactic treatment for chronic subdural hematoma, aimed at preventing recurrent bleeding on the brain's surface. Through these efforts, Edge Therapeutics seeks to address serious unmet medical needs in the field of neurology.

ContraFect Corporation is a clinical-stage biotechnology company based in Yonkers, New York, dedicated to developing innovative therapies for life-threatening and drug-resistant infectious diseases. Founded in 2008, the company focuses on creating therapeutic protein and antibody products, primarily using its proprietary lysin and monoclonal antibody platforms. Its lead candidate, CF-301, is an investigational lysin currently in Phase III trials for treating staphylococcus aureus bacteremia, including infections caused by methicillin-resistant strains. Additionally, ContraFect is advancing CF-296, which targets invasive staph aureus infections related to biofilms and osteomyelitis, and CF-370, aimed at gram-negative infections such as those caused by pseudomonas aeruginosa. The company also collaborates with The Rockefeller University to discover new lysin candidates targeting gram-negative pathogens and has initiated an expanded access program to provide exebacase for persistent bacteremia in COVID-19 patients.

BillMyParents delivers SuperSafe payment solutions that allow teens greater financial freedom, while giving parents the ability to easily track and control their spending. BillMyParents Supervised Shopping - With a simple email request and approval system, provides the independence young people crave and the control over spending that parents want - while ensuring that credit card numbers and personal information are kept safe and secure. BillMyParents is currently available as a payment solution at select online retail stores, in addition to social network, virtual worlds and online gaming web sites. The teen prepaid MasterCard extends BillMyParents into the offline world, the BillMyParents MasterCard Prepaid Card is accepted anywhere MasterCard debit cards are accepted and offers teens more options than ever before, meanwhile it provides advanced parental controls and spending insight that makes it a far superior option for parents than giving cash or sharing their own credit card information for purchases. Its Peace of Mind Control Panel provides the following parental benefits: - The ability to monitor transactions in real-time via email and/or SMS notifications - Instant lock / unlock of their teen’s card - Instant emergency funding for the teen — so they are never stranded without access to money in an emergency - Lost card protection (losing the card doesn’t lose the value on the card) - No credit implications for parents or their teens - No overdraft fees!